Who Owns Cervarix?

GSK began developing Cervarix in the early 2000s as part of its vaccines division's strategy to enter the HPV vaccine market. The vaccine was designed to protect against HPV types 16 and 18, which together account for approximately 70% of cervical cancer cases worldwide. GSK used its proprietary AS04 adjuvant system, which had been shown in clinical studies to produce a stronger and more durable immune response compared to conventional aluminum salt adjuvants.

The European Medicines Agency (EMA) approved Cervarix in September 2007 for the prevention of persistent infection and cervical lesions caused by HPV types 16 and 18. This approval came ahead of Merck's Gardasil in some European markets and gave GSK an early position in the European HPV vaccine market. The FDA approved Cervarix on October 16, 2009, for use in females aged 10 through 25 years for prevention of cervical cancer caused by HPV types 16 and 18.

Clinical trials for Cervarix included the PATRICIA study, one of the largest HPV vaccine trials ever conducted, involving over 18,000 women across 14 countries. Published in The Lancet in 2009, the study demonstrated that Cervarix provided high efficacy against HPV 16 and 18 infection and associated precancerous lesions. The trial also suggested cross-protection against some non-vaccine HPV types, including types 31, 33, and 45.

Despite strong clinical data, Cervarix faced significant commercial challenges. Merck's Gardasil, approved by the FDA in 2006, offered protection against four HPV types (6, 11, 16, and 18) and later nine types with Gardasil 9, approved in 2014. Gardasil's broader coverage against genital warts (types 6 and 11) in addition to cervical cancer made it the preferred choice for many national immunization programs. By 2014, Gardasil 9 had become the dominant HPV vaccine in the U.S. and most developed markets.

Cervarix was approved in over 100 countries and was used in national immunization programs in several countries including the United Kingdom, the Netherlands, and Japan. The UK adopted Cervarix for its national HPV vaccination program in 2008, but switched to Gardasil in 2012 following a procurement review that favored broader coverage.

GSK began discontinuing Cervarix in multiple markets starting around 2020. GSK's discontinued products list indicates that Cervarix Vaccine Pre-Filled Syringe was discontinued in the UK market by March 2021. In India, GSK Pharmaceuticals confirmed discontinuation of Cervarix as part of portfolio rationalization, as reported by The Hindu BusinessLine. The Therapeutic Goods Administration (TGA) of Australia cancelled Cervarix's registration on November 30, 2023, under Section 30(1)(c) of the Therapeutic Goods Act. GSK's Canadian product monograph for Cervarix was last revised in May 2024, indicating limited ongoing availability in some markets.

The discontinuation was driven by market economics. Gardasil 9's broader nine-valent coverage made it the standard of care in most markets, and the cost of maintaining separate manufacturing, regulatory filings, and distribution for a bivalent vaccine with declining sales was not commercially viable for GSK. GSK redirected its vaccines R&D resources toward other products including Shingrix (shingles vaccine) and Arexvy (RSV vaccine).

As of August 2026, Cervarix is not commercially available in most major markets. Some regulatory registrations may remain technically active in certain countries, but GSK has effectively withdrawn the product from active marketing and distribution.